A detailed history of Manchester Capital Management LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Manchester Capital Management LLC holds 3 shares of NBIX stock, worth $413. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3
Holding current value
$413
% of portfolio
0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 06, 2024

BUY
$130.4 - $143.74 $391 - $431
3 New
3 $0
Q3 2023

Nov 09, 2023

BUY
$94.02 - $117.1 $282 - $351
3 New
3 $0
Q1 2021

May 13, 2021

SELL
$87.57 - $119.4 $525 - $716
-6 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$86.91 - $108.33 $260 - $324
3 Added 100.0%
6 $1,000
Q3 2020

Oct 27, 2020

BUY
$96.16 - $135.15 $288 - $405
3 New
3 $0

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $13.2B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Manchester Capital Management LLC Portfolio

Follow Manchester Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Manchester Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Manchester Capital Management LLC with notifications on news.